Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors

S. Novello, G. V. Scagliotti, R. Rosell, M. A. Socinski, J. Brahmer, J. Atkins, C. Pallares, R. Burgess, L. Tye, P. Selaru, E. Wang, R. Chao, R. Govindan

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)1311
Number of pages1
JournalBritish Journal of Cancer
Issue number8
StatePublished - Apr 2010

Cite this